Poulton Stuart, EVP and Chief Development Officer at Karyopharm Therapeutics Inc. ($KPTI), sold shares on the open market four times in the last 365 days for a total of $54,673. His most recent sale occurred on March 2, 2026. These sales rank 10,301st among 11,678 individual insiders in our database, where the average is $8.6 million across 6.37 transactions. Poulton Stuart made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 5101 | $9.41 | 94,328.0000 | 18,343,968 | 5.13% | 0.03% |
| Feb. 17, 2026 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 378 | $8.63 | 99,429.0000 | 18,343,968 | 0.38% | 0.00% |
| Jan. 31, 2026 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | A | Common Stock | 32415 | $0.00 | 99,807.0000 | 17,050,876,000 | 48.10% | 0.00% |
| Oct. 15, 2025 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | A | Common Stock | 39682 | $0.00 | 67,392.0000 | 126,240,054 | 143.20% | 0.03% |
| Sept. 12, 2025 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | A | Common Stock | 888 | $0.00 | 28,111.0000 | 126,240,054 | 3.26% | 0.00% |
| Sept. 15, 2025 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 401 | $6.43 | 27,710.0000 | 126,240,054 | 1.43% | 0.00% |
| July 29, 2025 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 191 | $4.37 | 27,223.0000 | 126,240,054 | 0.70% | 0.00% |
| March 4, 2025 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 3548 | $6.29 | 27,414.0000 | 126,240,054 | 11.46% | 0.00% |
| Feb. 28, 2025 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | A | Stock Option (right to buy) | 10000 | $0.00 | 10,000.0000 | 126,240,054 | 9999.99% | 0.01% |
| Feb. 28, 2025 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | A | Stock Option (right to buy) | 9166 | $0.00 | 9,166.0000 | 126,240,054 | 9999.99% | 0.01% |
| Feb. 28, 2025 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | A | Common Stock | 4583 | $0.00 | 30,962.0000 | 126,240,054 | 17.37% | 0.00% |
| Feb. 28, 2025 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | A | Common Stock | 5000 | $0.00 | 26,379.0000 | 126,240,054 | 23.39% | 0.00% |
| Feb. 18, 2025 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 5914 | $0.63 | 320,714.0000 | 126,240,054 | 1.81% | 0.00% |
| July 30, 2024 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 2883 | $1.06 | 326,628.0000 | 0 | 0.87% | 0.00% |
| March 1, 2024 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common | 6155 | $1.20 | 329,511.0000 | 0 | 1.83% | 0.00% |
| Feb. 29, 2024 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common | 16311 | $1.17 | 335,666.0000 | 0 | 4.63% | 0.00% |
| Feb. 28, 2024 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | A | Common Stock | 188205 | $0.00 | 351,977.0000 | 0 | 114.92% | 0.00% |
| Feb. 15, 2024 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 99 | $1.40 | 163,772.0000 | 0 | 0.06% | 0.00% |
| Feb. 15, 2024 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 5748 | $1.33 | 163,871.0000 | 0 | 3.39% | 0.00% |
| Jan. 24, 2024 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | A | Common Stock | 13333 | $0.00 | 169,619.0000 | 0 | 8.53% | 0.00% |
| July 28, 2023 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 2845 | $1.70 | 156,286.0000 | 0 | 1.79% | 0.00% |
| Feb. 28, 2023 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | A | Common Stock | 95000 | $0.00 | 159,131.0000 | 0 | 148.13% | 0.00% |
| Feb. 15, 2023 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 5665 | $3.19 | 64,335.0000 | 0 | 8.09% | 0.00% |
| Feb. 15, 2023 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 8 | $3.23 | 64,327.0000 | 0 | 0.01% | 0.00% |
| Feb. 15, 2023 | Karyopharm Therapeutics Inc. | $KPTI | Poulton Stuart | EVP, Chief Development Officer | S | Common Stock | 196 | $3.16 | 64,131.0000 | 0 | 0.30% | 0.00% |